Navigation Links
Genstruct Added to The Biomarker Consortium's Rapidly Growing Roster of Industry Experts
Date:11/4/2008

CAMBRIDGE, Mass., Nov. 4 /PRNewswire/ -- Genstruct Inc., a systems biology company focused on identifying molecular mechanisms, networks and biomarkers to better develop novel therapeutics and molecular diagnostics, today announced that it has become a member of The Biomarker Consortium, a public/private research partnership managed by the Foundation for the National Institutes on Health (FNIH), and founded by the National Institutes of Health (NIH), the Food and Drug Administration (FDA) and the Pharmaceutical Research and Manufacturers of America (PhRMA).

"Being an active contributor in The Biomarker Consortium's initiatives to discover, develop and qualify biological markers to support new drug development, preventative medicine and medical diagnostics is an excellent opportunity for Genstruct to share our knowledge as well as collaborate with other industry experts to help accelerate drug discovery and development," said Dr. Keith O. Elliston, president and CEO at Genstruct. "Our technology allows one to identify mechanism-based biomarkers which can then be qualified and validated in clinical studies rather than working backwards from clinical correlations, enabling us to provide a unique viewpoint to this group based on our experience."

Biomarkers (biological markers) are molecular, biological or physical characteristics that indicate a specific, underlying physiologic state to identify risk for disease, to make a diagnosis and to guide treatment, according to The Biomarker Consortium. The group aims to rapidly identify and qualify biomarkers to support basic and translational research, guide clinical practice and, ultimately, support the development of safe and effective medicines and treatments.

Genstruct's proprietary Causal Network(TM) Modeling platform for systems biology enables scientists to break down cognitive barriers that impede critical path research. Genstruct's computable models of biology lead directly to the discovery of compound mechanisms of action (MOA) and biomarkers of safety and efficacy. Its scientists leverage the system and methodologies for internal research programs as well as research partnerships with pharmaceutical companies in order to streamline drug discovery and development and improve clinical trial design and implementation.

Dr. Elliston added, "We have initially focused on three core disease areas at Genstruct: oncology, metabolic disorders and inflammation. These are all key areas of research for The Biomarker Consortium as well. We believe that the identification of molecular mechanisms and mechanistic biomarkers in these disease areas through systems biology approaches will ultimately lead to better decisions, lower product failure rates, optimal clinical trial design and execution and faster FDA product approval."

About Genstruct

Founded in 2002, Genstruct is a systems biology company focused on elucidating the complexity of biology for the development of safe and effective therapeutics and molecular diagnostics. By developing Causal Network(TM) models for complex biological systems, Genstruct develops a deep molecular understanding of diseases and drug action, and designs mechanistic biomarkers and molecular diagnostics to facilitate drug development and personalized medicine. Genstruct's Consulting Services division engages in short-, mid- and long-term partnerships with top tier pharmaceutical and life sciences companies, to develop new therapeutics and mechanistic biomarkers in the areas of oncology, metabolic disorders, cardiovascular diseases and inflammation. Genstruct was awarded the Bio-IT World 2008 Best Practices Award in the Drug Discovery & Development category for its joint collaboration with Sirtris Pharmaceuticals (a GSK company). Genstruct is a privately held company based in Cambridge, Mass. For more information, please visit http://www.genstruct.com.

Genstruct and the Genstruct logo are registered trademarks and Causal Network Model and Knowledge Assembly are trademarks of Genstruct, Inc. All other trademarks or registered trademarks are properties of their respective owners.

Contact:

Karen Higgins

A & E Communications for Genstruct

(610) 831-5723

khiggins@aandecomm.com


'/>"/>
SOURCE Genstruct Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Genstruct CEO, Dr. Keith Elliston, Invited to Speak at Oncology Clinical Trial Summit
2. Genstructs Andrea Matthews Selected for Mass High Techs People to Watch Under 30
3. Genstruct and Sirtris Pharmaceuticals Win Bio-IT Worlds Best Practices Award
4. Genstruct Names Louis Latino VP of Sales
5. Genstruct Expands Team with New VP of Engineering
6. Ranexa(R) Added to New ACC/AHA Guidelines on Unstable Angina/Non ST-Elevation Myocardial Infarction (UA/NSTEMI)
7. Eurand Added to NASDAQ Biotechnology Index
8. Biodel Inc. Added to NASDAQ Biotechnology Index
9. Fungitell(R) CE Marked, Referenced in IDSA and NCCN Guidelines and Added to EORTC-MSG Revised Definitions of Invasive Fungal Disease
10. Caliper Life Sciences Added to Russell 3000(R) Index
11. Bioheart, Inc., Added to Russell Microcap Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 A person commits ... the crime scene to track the criminal down. ... U.S. Food and Drug Administration (FDA) uses DNA evidence to ... Sound far-fetched? It,s not. The FDA has ... to support investigations of foodborne illnesses. Put as simply as ...
(Date:6/23/2016)... June, 23, 2016  The Biodesign Challenge (BDC), a ... ways to harness living systems and biotechnology, announced its ... in New York City . ... students, showcased projects at MoMA,s Celeste Bartos Theater during ... , MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... ... June 23, 2016 , ... In a new case report published today in ... patient who developed lymphedema after being treated for breast cancer benefitted from an injection ... for dealing with this debilitating, frequent side effect of cancer treatment. , ...
(Date:6/23/2016)... 2016 On Wednesday, June 22, 2016, ... 0.22%; the Dow Jones Industrial Average edged 0.27% lower to ... down 0.17%. Stock-Callers.com has initiated coverage on the following equities: ... (NASDAQ: NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ... BIND ). Learn more about these stocks by accessing their ...
Breaking Biology Technology:
(Date:4/19/2016)... 20, 2016 The new GEZE ... compact web-based "all-in-one" system solution for all door components. ... or the door interface with integration authorization management system, ... systems. The minimal dimensions of the access control and ... building installations offer considerable freedom of design with regard ...
(Date:4/13/2016)... CHICAGO , April 13, 2016  IMPOWER physicians ... are setting a new clinical standard in telehealth ... By leveraging the higi platform, IMPOWER patients can ... weight, pulse and body mass index, and, when they ... quick and convenient visit to a local retail location ...
(Date:3/23/2016)... Massachusetts , March 23, 2016 /PRNewswire/ ... im Interesse erhöhter Sicherheit Gesichts- und Stimmerkennung ... Xura, Inc. (NASDAQ: MESG ), ... bekannt, dass das Unternehmen mit SpeechPro zusammenarbeitet, ... aus der Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, ...
Breaking Biology News(10 mins):